Dearest Readers, you know how the words "free" and "CRPS research" are as enticing to me as cataria nepeta to the felines! Nonetheless, the usual caveats are in force. This is not a research study but a case report. Still, as I recently reminded everyone, the entire impetus behind studying ketamine in relationship to CRPS came about as a result of observations made in a single case study, so I withhold judgment. This is something that I suppose could be tried with the assistance of a willing and experienced neurologist or pain management specialist and a compounding pharmacist. Those of us who cannot tolerate creams due to severe allodynia look forward to hearing from those of you still able to slather the stuff on!
Treatment of chronic regional pain syndrome type 1 with palmitoylethanolamide and topical ketamine cream: modulation of nonneuronal cells.
PMID: 23658493 [PubMed] PMCID: PMC3643547
Before/After Photos:
Treatment of chronic regional pain syndrome type 1 with palmitoylethanolamide and topical ketamine cream: modulation of nonneuronal cells.
Jan M Keppel Hesselink1 and David J Kopsky2
1Institute for Neuropathic Pain, Bosch en Duin, The Netherlands;
2Institute for Neuropathic Pain, Amsterdam, The Netherlands
Correspondence: Jan M Keppel Hesselink, Institute for Neuropathic Pain, Spoorlaan 2a, 3735 Bosch en Duin, The Netherlands, Tel +31 30 6910932, Email jan@neuropathie.nu
ABSTRACT
Chronic regional pain syndrome (CRPS) can be intractable to treat and patients sometimes suffer for many years. Therefore, new treatment strategies are needed to alleviate symptoms in CRPS patients. This case report describes a patient suffering from intractable CRPS type 1 for 13 years. Due to her swollen painful feet and left knee she is wheelchair-bound. The combination of palmitoylethanolamide and ketamine 10% cream reduced her pain by more than 50% after 1 month of treatment, and a marked reduction in swelling and skin discoloration was noticed. Furthermore, she could walk independently again and she experienced no side effects. Thus, palmitoylethanolamide and topical ketamine could be a combination therapy option for treating CRPS patients.
KEYWORDS:
CRPS, cream, endocannabinoid, ketamine, mast cells, palmitoylethanolamide, sudeck
PMID: 23658493 [PubMed] PMCID: PMC3643547
Before/After Photos:
No comments:
Post a Comment
The Haddock Corporation's newest dictate: Anonymous comments are no longer allowed. It is easy enough to register and just takes a moment. We look forward to hearing from you non-bots and non-spammers!